T1	intervention 0 9	Nebivolol
T2	condition 20 54	doxorubicin-induced cardiotoxicity
T3	total-participants 258 260	60
T4	age 277 290	52.6Â±13 years
T5	eligibility 292 373	with HER2 negative breast cancer, scheduled to undergo treatment with doxorubicin
T6	intervention-participants 450 452	30
T7	control 536 549	control group
T8	control-participants 553 555	30
T10	outcome 933 983	baseline clinical and echocardiographic parameters
T11	outcome 1061 1065	died
T12	outcome 1105 1113	withdrew
T14	outcome 1289 1326	Tissue Doppler imaging (TDI) detected
T15	outcome 1523 1564	alteration of the ventricular deformation
T16	outcome 1663 1716	alterations in the LV systolic and diastolic function
T9	outcome 1178 1217	left ventricular (LV) ejection fraction
T13	outcome 1219 1238	shortening fraction
T17	outcome 1244 1256	LV diameters
